CD274 and neoplasm: The lung immuno-oncology prognostic score (LIPS-3), which includes NLR, PD-L1 tumor cell expression level, and LDH, was developed to classify NSCLC patients with PD-L1 ≥50% who received first-line pembrolizumab and showed that NLR <4 was a significant prognostic factor (26).